JAGX
Jaguar Health Inc
NASDAQ · Pharmaceuticals
$0.67
+0.08 (+13.12%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 820.8K | 728.2K | 878.3K |
| Net Income | 214.7K | 171.9K | 200.8K |
| EPS | — | — | — |
| Profit Margin | 26.2% | 23.6% | 22.9% |
| Rev Growth | +12.4% | -5.9% | +16.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 606.5K | 719.4K | 546.9K |
| Total Equity | 1.46M | 1.37M | 1.50M |
| D/E Ratio | 0.42 | 0.52 | 0.37 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 270.0K | 249.9K | 289.1K |
| Free Cash Flow | 118.6K | 132.1K | 184.4K |